1012-2966

S1012-29662025000100138

10.47993/gmb.v48i1.965

Brasil

España

00 00 2025

48 1 138 145

2008 371 9614 9614

760-70

2013 3 1 1

90-5

2010 65 2 2

161-6

World Health Organization

1996

2014 43 5 5

1542-62

2010 13 5 5

419-28

2022 63 3 3

2018 69 4 4

249-59

1993 44 3 3

231-5

2015 1

2005 52 ^sSuppl 1 ^sSuppl 1 Suppl 1

S7-S22

2019 59 2 2

196-212

2022 81

3-7

2015 44 3 3

497-515

2007 10 6 6

247-57

2006 96 7 7

1226-35

2005 118 ^sSuppl 12B ^sSuppl 12B Suppl 12B

14-24

2024 27 3 3

223-5

Study of Women's Health Across the Nation

2015 175 4 4

531-9

2014 21 9 9

924-32

2024 11 1 1

2018 45 4 4

585-97

2001 76 5 5

874-8

STRAW 10 Collaborative Group

2012 19 4 4

387-95

2005 55 4 4

363-8

2006 91 8 8

3034-40

2012 75 2 2

70-4

2012 98 4 4

1037-42

2004 11 6 Pt 1 6 Pt 1

601-6

2002 77 2 2

357-62

2007 13 6 6

559-65

1999 84 11 11

4025-30

2007 92 8 8

3060-7

2020 27 6 6

611-3

2020 1242

89-120

2021 27 6 6

1115-50

2023 329 5 5

405-20

2022 28 3 3

208-23

Writing Group for the Women's Health Initiative Investigators

2002 288 3 3

321-33

2021 12

2024 37 3 3

736-40

2024 144 1 1

12-23

2024 184

2024 37 3 3

736-40

"The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel

2022 29 7 7

767-94

2022 163

62-81

IMS Writing Group

2016 19 2 2

109-50

2020 20 1 1

71-85

2007 17 9 9

1315-24

2009 114 6 6

1197-204

North American Menopause Society

2003 10 6 6

497-506

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial The Writing Group for the PEPI Trial

1996 275 5 5

370-5

2020 27 8 8

918-28

2018 41 2 2

247-52

NAMS Group of the AEEM

2005 8 1 1

36-48

2005 172 1 1

57-9

2021 42 6 6

720-52

2024 37 3 3

736-40

2024 31 5 5

363-71

2024 144 1 1

12-23

2024 47 1 1

72-85

2024 403 10430 10430

947-57

2024 27 3 3

223-5

2022 11 1 1

66-79

2024 6 3 3

94-101